- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
FDA, AHRQ look to boost drug effectiveness, safety
The FDA and the Agency for Healthcare Research & Quality (AHRQ) will launch an effort to advance scientific research and foster research partnerships on drug effectiveness and safety. Beginning in mid-January, Anne Trontell, M.D., FDA's deputy director of the Office of Drug Safety (ODS), will embark on a 12-month FDA-sponsored detail as a senior adviser in pharmaceutical outcomes research in AHRQ's Center for Outcomes and Effectiveness. She will promote collaborative drug safety and effectiveness research by the FDA, AHRQ, CMS, and academic and professional organizations. Her duties will include participation in effectiveness and risk communication research and outreach conduction by the new AHRQ Effective Health Care Program authorized under the Medicare Modernization Act.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
